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Signal-Regulated Activation of Serum Response
Factor Is Mediated by Changes in Actin Dynamics
SRF in the absence of extracellular signals; Cdc42 and
Rac1 function independently of RhoA, but their relevance
to regulation of SRF by extracellular signals remains
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John Copeland, and Richard Treisman*
Transcription Laboratory
Imperial Cancer Research Fund Laboratories unclear (Hill et al., 1995). Since serum- and LPA-induced
activation of SRF does not require known posttransla-44 Lincoln's Inn Fields
London WC2A 3PX tional modifications of the protein, we have previously
proposed that it is mediated by an as yet uncharacter-United Kingdom
ized SRF accessory factor (Hill et al., 1994; Johansen
and Prywes, 1994).
RhoA controls diverse cellular processes concernedSummary
with the cytoskeleton, including PIP2 synthesis, actin
polymerization, F-actin bundling, myosin-based con-Serum response factor (SRF) regulates transcription
tractility, focal adhesion formation, and cytokinesis.of many serum-inducible and muscle-specific genes.
Constitutively active RhoA can transform fibroblasts,Using a functional screen, we identified LIM kinase-1
and Ras-induced transformation and cell cycle reentryas a potent activator of SRF. We show that SRF activa-
is Rho dependent (reviewed by Van Aelst and D'Souza-tion by LIM kinase-1 is dependent on its ability to regu-
Schorey, 1997). Studies with RhoA and Rac effector looplate actin treadmilling. LIM kinase activity is not essen-
mutants show that SRF activation does not correlatetial for SRF activation by serum, but signals depend
with transformation or cytoskeletal rearrangements buton alterations in actin dynamics. Studies with actin-
have failed to identify the effector proteins involvedbinding drugs, the actin-specific C2 toxin, and actin
(Westwick et al., 1997; Sahai et al., 1998; Zohar et al.,overexpression demonstrate that G-actin level con-
1998). Although the RhoA effector kinase ROCK cantrols SRF. Regulation of actin dynamics is necessary
activate SRF, this process is itself Rho dependent, andfor serum induction of a subset of SRF target genes,
ROCK activity does not appear necessary for serum-including vinculin, cytoskeletal actin, and srf itself, and
induced SRF activation (Chihara et al., 1997; Sahai etalso suffices for their activation. Actin treadmilling
al., 1998, 1999). The mechanism of SRF activation andprovides a convergence point for both serum- and LIM
its relationship to other RhoA-controlled processes haskinase-1-induced signaling to SRF.
therefore remained unclear.
We developed an in vivo functional screen for SRF
activators and describe here its use to identify the actinIntroduction
regulator LIM kinase-1 (LIMK-1) as a powerful SRF acti-
vator. We show that although LIMK-1 is not essentialThe MADS box transcription factor serum response fac-
tor (SRF) regulates both cellular immediate-early genes for serum-regulated activation of SRF, it is the ability of
both LIMK-1 and extracellular signals to regulate theand genes expressed in skeletal, smooth, and cardiac
muscle (for references, see Arsenian et al., 1998). Like actin treadmilling cycle that regulates SRF activity.
Depletion of G-actin is both necessary and sufficient formany transcription factors, SRF exhibits combinatorial
interactions with other transcription factors. At the activation both of SRF reporters and a subset of SRF
target genes. Our results show that the actin treadmillinggrowth factor±regulated c-fos serum response element,
it forms a ternary complex with members of the ternary cycle represents a convergence point in signaling path-
ways to SRF and reveal a direct link between cytoskele-complex factor (TCF) family of Ets domain proteins,
whose activity is regulated by MAP kinase signaling tal reorganization and gene transcription.
pathways (for review, see Treisman, 1994). In contrast,
at muscle-specific promoters, SRF acts cooperatively Results
with other transcription factors, including GATA-4, Nkx2.5,
and the myogenic group of E box proteins (Sartorelli Expression Screening for SRF Activators
et al., 1990; Chen et al., 1996; Durocher et al., 1997; To establish an in vivo screening assay for SRF activa-
Sepulveda et al., 1998). tors, we first constructed an indicator COS cell line,
Extracellular signals can also control SRF activity in COS/3DA.CD8, containing an SRF-controlled CD8 re-
the absence of TCF binding by a pathway that involves porter gene (see Experimental Procedures). These cells
Rho family GTPases. Serum- or lysophosphatidic acid were then used to screen a VP16-tagged NIH3T3 cDNA
(LPA)-induced activation of SRF is dependent on func- library by FACS sorting for cell-surface CD8 expression.
tional RhoA, as is the apparently constitutive activity We expected to recover two types of activator: cDNAs
of SRF at muscle-specific promoters (Hill et al., 1995; that stimulate transcription directly, encoding proteins
Carnac et al., 1998; Wei et al., 1998). Expression of that interact with SRF or proteins bound to it; and
constitutively active forms of both RhoA and other Rho cDNAs that act indirectly, encoding proteins that acti-
family GTPases such as Cdc42 and Rac1 can activate vate SRF-linked signal transduction pathways (Figure
1A). Following sorting, DNA was recovered from the top
0.7% of CD8-expressing cells and divided into pools of* To whom correspondence should be addressed (e-mail: treisman@
icrf.icnet.uk). 50 plasmids. Of 150 pools screened, 5 positive pools
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Figure 1. Cos Cell Expression Screen for SRF Activators
(A) Experimental strategy. Left panel, the SRF-controlled reporter Figure 2. LIMK-1 Is a Strong Activator of SRF
in 3D.ACD8 cells is shown with the SRF dimer as shaded circles, (A) LIMK-1 activates the SRF-linked signaling pathway. Left panel,
and below are two expected scenarios for activation of the reporter behavior of different c-fos SRE derivatives: SRE.WT binds both SRF
gene by VP16-tagged cDNAs. Right panel, the screening protocol. and TCF; SRE.L binds SRF only; SRE.LM binds neither SRF nor
(B) Sibling selection of a positive pool. FACS analysis of positive TCF. LIMK-1 derivatives used are shown in (B). SRF.M2-VP16 is an
pool 20 (thick lines) compared to cells transfected with vector alone altered-specificity SRF that can activate the SRE.LM reporter (Hill
(thin lines). et al., 1994). NIH3T3 cells were transfected using DEAE-dextran;
(C) Schematic representation of the clones isolated in the screen data shown are from a representative experiment. Right panel,
compared with the intact proteins. LIMK-1 does not activate the ternary complex factor Elk-1. Cells
were transfected with the reporter LexOP.CAT together with expres-
sion plasmids encoding the LexA/Elk-1 fusion protein NLex.ElkC
and LIMK-1 derivatives. Data shown represent the mean 6 SEM
were identified and the active plasmids isolated by sib- from three independent transfections.
ling selection (Figure 1B). Two different partial cDNAs (B) LIMK-1 and LIMK-2 derivatives used in this paper. Point muta-
were recovered (Figure 1C): clone G5, encoding mouse tions are represented by black lines.
(C) LIMK-1 kinase activity is required for SRF activation. NIH3T3SRF residues 59±276, which encompass the DNA-bind-
cells were transfected with the SRF-controlled 3D.ACAT reportering domain, and clone Q1, which encodes mouse LIMK-1
together with the indicated activators. Data shown represent theresidues 293±646, including the kinase domain. The re-
mean 6 SEM from at least three independent transfections.
peated isolation of these cDNAs (G5, twice; Q1, three
times) shows that under the screening conditions used,
while mutation of the SRF-binding site abolished activa-the library was screened at saturation.
tion (Figure 2A). The VP16 tag was not required for acti-
vation, suggesting that activation occurs via the action
of the kinase (Figure 2A). Neither intact LIMK-1 nor itsActivation of SRF by LIM Kinases
LIMK-1 and its close relative LIMK-2 define a novel fam- kinase domain alone could activate the MAP kinases
ERK2 and SAPK/JNK (data not shown), and, consistentily of serine/threonine kinases containing two N-terminal
LIM motifs and a PDZ domain (Bernard et al., 1994; with this, they did not activate a reporter system con-
trolled by the MAPK-controlled TCF Elk-1 (Figure 2A,Mizuno et al., 1994). To investigate the specificity of
transcriptional activation by LIMK-1, we first performed right panel). We next compared the ability of several
LIMK-1 and LIMK-2 derivatives, shown in Figure 2B,transfection assays using reporters controlled by vari-
ous derivatives of the c-fos SRE (Hill et al., 1994; Figure to activate the SRF-controlled reporter gene 3D.ACAT
(Mohun et al., 1987; Hill et al., 1995). LIMK derivatives2A). Clone Q1 activated the wild-type c-fos SRE at levels
comparable to SRF-VP16 or serum stimulation; mutation activated SRF at levels comparable to that by activated
Rho family GTPases. The isolated LIMK-1 kinase domainof the TCF-binding site actually increased activation,
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was more effective than that of LIMK-2, and both were
more effective than the intact proteins, even though all
were expressed at similar levels (Figure 2C; data not
shown); it is likely that this reflects the increased activity
of the isolated kinase domain (Edwards and Gill, 1999).
SRF activation by LIMK-1 was abolished by kinase-inac-
tivating mutations (Yang et al., 1998; Edwards and Gill,
1999); these mutations also inactivated VP16-tagged clone
Q1, indicating that activation cannot occur via two hy-
brid interactions between the kinase and the reporter
gene. Taken together, these results show that LIM kinases
specifically activate the SRF-linked signal pathway.
LIMK-1-Induced SRF Activation Requires
F-Actin Stabilization
Currently, the only known LIMK substrates are the cofi-
lins, small actin-binding proteins that facilitate the disso-
ciation of actin monomers from F-actin pointed ends
(see Figure 3A; Carlier et al., 1997; Lappalainen and
Drubin, 1997). Phosphorylation of cofilin at serine 3 by
LIMKs prevents its interaction with actin and thereby
stabilizes F-actin. Overexpression of LIMK-1 therefore
promotes formation of F-actin aggregates, an effect that
can be blocked by coexpression of the nonphosphory-
latable cofilin mutant Cof-S3A (Arber et al., 1998; Yang
et al., 1998). We exploited this observation to test
whether SRF activation by LIMK-1 is mediated via its
effect on F-actin.
NIH3T3 cells were microinjected with LIMK and cofilin
expression plasmids, together with the SRF-controlled
reporter 3D.FosHA. The LIMK-1 kinase domain induced
formation of large F-actin aggregates, as did intact
LIMK-1, although less effectively, and this required ki-
nase activity (Figure 3B; data not shown). Both intact
LIMK-1 and its kinase domain also activated the coin-
Figure 3. LIMK-1 Activates SRF via Actinjected SRF reporter gene (Figure 3C). Expression of Cof-
(A) Regulation of actin treadmilling by LIM kinases. Actin monomersS3A but not wild-type cofilin blocked formation of actin
are shown as wedges, cofilin as a solid circle, and profilin as a solidaggregates by LIMK-1 or its kinase domain (Figure 3B;
rectangle. Cofilin facilitates dissociation of monomers from F-actin
data not shown) and substantially inhibited activation pointed ends, while polymerization is dependent on Rho family
of the SRF-controlled reporter gene (Figure 3C). These GTPases. LIM kinases phosphorylate cofilin, preventing its interac-
effects were dependent on interaction of the mutant tion with actin and thereby stabilizing F-actin.
(B) Cofilin S3A blocks disruption of the actin cytoskeleton by LIMK-1.cofilin with actin, since neither phenotype was affected
NIH3T3 cells in 0.5% FCS were microinjected with plasmids en-by coexpression of Cof-S3A/K112,114A, a mutant that
coding the LIMK-1 kinase domain (50 mg/ml) and cofilin derivativescan neither be phosphorylated nor bind actin (Figures
(100 mg/ml). F-actin was visualized 5 hr later using Texas red±
3B and 3C; see Lappalainen et al., 1997). These results phalloidin. Microinjected cells are arrowed.
strongly suggest that the ability of LIMK-1 derivatives (C) Cells were microinjected with the SRF-controlled reporter
to activate SRF is dependent on its ability to regulate 3D.AFosHA (50 mg/ml) together with LIMK-1 and cofilin vectors as
in (B). After 14 hr, cells were either stained for FosHA expressionactin treadmilling.
or stimulated with LPA or 10% FCS, incubated a further 1 hr, andWe used overexpression of Cof-S3A or kinase-inac-
fixed before staining. Data are mean 6 SEM from three independenttive LIMK-1 to test whether SRF regulation by extracellu-
experiments.
lar signals also requires cofilin phosphorylation by LIMK. (D) Dominant-negative LIMK-1 does not prevent serum induction.
Under conditions sufficient to block activation by coin- Cells were microinjected with SRF-controlled reporter 3D.AFosHA
together with the kinase-inactive derivative K1.C/D460A-T508V andjected LIMK-1, Cof-S3A expression had no effect on
processed as in (C). Data are mean 6 SEM from three independentSRF activation by serum and only a marginal effect on
experiments. Similar results were obtained with K1.C/D460A.that by LPA (Figure 3C). Similarly, under conditions
where the kinase-inactive LIMK-1 mutant D460A/T508V
(Edwards and Gill, 1999; see Figure 2B) could partially SRF Activation by LIMK-1 Is Largely
inhibit SRF activation by LIMK-1, it had no effect on SRF Dependent on RhoA
activation by serum or LPA (Figure 3D). Together, these LIMKs and Rho GTPases affect different aspects of actin
data show that although LIMK-1 regulates SRF activity treadmilling: LIMKs prevent the dissociation of actin
via its effects on actin, its activity is not essential for from filament pointed ends, while Rho GTPases promote
the accumulation of F-actin (Figure 3A; reviewed by Van
Cell
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Figure 4. SRF Activation by LIMK-1 Is Largely Dependent on RhoA
(A) Both cytoskeletal rearrangements and SRF activation by LIMK-1 are RhoA dependent. NIH3T3 cells were microinjected with plasmids
encoding LIMK-1 derivatives (100 mg/ml) and C3 transferase (25 mg/ml) together with the SRF-controlled reporter 3D.AFosHA (50 mg/ml). Five
hours later, FosHA protein was detected by indirect immunofluorescence and F-actin visualized using Texas red±phalloidin. Microinjected
cells, identified by staining for LIMK-1, are arrowed. Similar results were observed when endogenous RhoA was sequestered by coexpression
of the RhoA-binding domain of its effector kinase PKN (data not shown).
(B) Sensitivity of SRF activation to C3 transferase in the microinjection assay. Data represent mean 6 SEM from three independent microinjection
experiments performed as in (A).
(C) SRF activation by LIMK-1 is largely RhoA dependent in the transfection assay. NIH3T3 cells were transfected with the SRF-controlled
3D.ACAT reporter together with the indicated activators. Data shown represent the mean 6 SEM from three independent transfections.
Aelst and D'Souza-Schorey, 1997; Wasserman, 1998; Bi while LIMK-2 was RhoA dependent at all concentrations
of input plasmid (Figure 4C).and Zigmond, 1999). Since even serum-starved cells
possess basal levels of RhoA activity (C. Hill, A. S. Al- These results show that in serum-starved NIH3T3
cells, LIMK-induced actin rearrangements and SRF acti-berts, and R. T., unpublished data), we used C3 trans-
ferase, which inactivates RhoA and its close relatives, vation are substantially dependent on basal levels of RhoA
signaling. Actin treadmilling therefore represents a po-to test whether LIMK-induced SRF activation and actin
reorganization were dependent on RhoA. tential convergence point for LIMK- and Rho-dependent
signaling to SRF.In microinjection assays, expression of C3 transferase
antagonized the formation of F-actin aggregates in cells
expressing the LIMK-1 kinase domain expression plas- Actin Polymerization Inhibitors Prevent SRF Activation
by LIMK-1, Rho Family GTPases,mid and had a similar effect on the less dramatic actin
rearrangements induced by intact LIMK-1, LIMK-2, or and Extracellular Signals
To examine the role of actin dynamics in SRF activa-the LIMK-2 kinase domain (Figure 4A, upper panels, and
data not shown). LIMK-1 expression partially alleviated tion more directly, we tested the effects of actin poly-
merization inhibitors. Cells were treated either with thethe cytoskeletal disruption induced by C3 transferase,
demonstrating that functional RhoA is not essential for toxin latrunculin B, which sequesters G-actin monomers
(Coue et al., 1987), or with Clostridium botulinum C2LIMK activity (data not shown; Figure 4A, upper panels;
see Discussion). Activation of SRF by intact LIMK-1 or toxin, which prevents polymerization of actin by ADP-
ribosylating it at residue R177 (Vandekerckhove et al.,LIMK-2 was strongly inhibited by C3 transferase. How-
ever, SRF activation by the LIMK-1 kinase domain was 1988).
We first tested the effect of latrunculin B treatment ononly partially inhibited at low plasmid input and appar-
ently unaffected at high plasmid concentration (Figures activation of SRF induced by cotransfection of signaling
components. Latrunculin B significantly impaired activa-4A and 4B; see Discussion). Similar results were ob-
tained in the more quantitative transfection assay: SRF tion of the SRF reporter 3DA.CAT by LIMK-1 derivatives,
constitutively active Rho family GTPases, and the acti-activation by the LIMK-1 kinase domain was sensitive
to C3 transferase at low plasmid concentrations but vated RhoA exchange factor mNet1DN; it did not affect
activation by the constitutively active SRF derivativesubstantially RhoA independent at high plasmid inputs,
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RhoA (Hill et al., 1995). For these experiments, we per-
formed RNase protection assays using the NIH3T3-
derived cell line SRE.FosHA, which carries an integrated
SRF-controlled reporter gene (Alberts et al., 1998). La-
trunculin B treatment completely blocked serum- and
LPA-induced transcription of the reporter (Figure 5C).
Similar results were obtained upon treatment of the cells
with C2 toxin (Figure 5D). Taken together, these data
show that although LIMK is not required for serum-
induced SRF activation, both LIMK- and serum-induced
signals acting through RhoA converge at the level of
actin treadmilling.
Induction of SRF by Actin-Polymerizing Agents
The experiments described in the preceding sections
suggest that stimuli that activate SRF do so by inducing
F-actin accumulation. We therefore tested the effect
on SRF activity of other drugs and proteins known to
increase F-actin levels. These agents include jasplaki-
nolide, which binds to and stabilizes F-actin (Bubb et
al., 1994), and proteins belonging to the WASP and Di-
aphanous families that promote actin polymerization
(Beckerle, 1998; Wasserman, 1998; Bi and Zigmond, 1999).
Jasplakinolide strongly activated transcription of theFigure 5. Inhibition of Actin Polymerization by Latrunculin or C. bot-
SRF reporter gene in SRE.FosHA cells, although withulinum C2 Toxin Inhibits SRF Activation
somewhat slower and more prolonged kinetics than se-(A) Latrunculin B inhibits SRF but not TCF. Cells were transfected
with reporters and activator plasmids as indicated. Eight hours after rum (Figure 6A). Latrunculin B pretreatment retarded
the start of the transfection, latrunculin B was added; cells were jasplakinolide-induced SRF activation but did not block
harvested 12 hr later. Left panel, SRF-controlled 3D.ACAT reporter. it, consistent with the fact that the two drugs bind revers-
Data are mean 6 SEM from three independent transfections, with
ibly to different types of actin target (Figure 6A). Jasplak-activity in the absence of inhibitor set to 100 (see Figure 2C). Right
inolide also activated the transfected SRF-controlledpanel, Elk-1-controlled Nlex.ElkC/LexOP.CAT reporter system.
reporter 3D.ACAT (Figure 6B) but did not activate the(B) NIH3T3 cells maintained in 0.5% FCS for 24 hr were stimulated
with 10% FCS for the indicated times or for 30 min with 50 ng/ml MAP kinase±controlled Elk-1 TCF reporter gene system
anisomycin (aniso), UV irradiation (UV), or 0.5 mM jasplakinolide; or MAP kinases (data not shown, see Figure 5B). Overex-
latrunculin B pretreatment (60 min) was as indicated. Cell lysates pression of the WASP family proteins VASP, WASP, and
were analyzed by immunoblotting with ERK2 or phospho-JNK anti-
N-WASP activated the SRF-controlled reporter, and thebodies.
C-terminal 110 residues of N-WASP (VCA), which are(C) Latrunculin B blocks SRF activation by serum and LPA. SRE.FosHA
sufficient to promote actin polymerization in vitro (Ma-cells, which contain the SRF-controlled reporter 3D.AFosHA, were
serum starved for 36 hr. Following a 60 min latrunculin B pretreat- chesky and Gould, 1999; Rohatgi et al., 1999), were also
ment as indicated, cells were stimulated with 15% FCS or 10 mM sufficient for SRF activation (Figure 5C). Removal of the
LPA for 30 min before analysis by RNase protection for 3D.AFosHA N-terminal Rho-binding domains of mDia1 and mDia2
and GAPDH transcripts. Latrunculin B did not affect endogenous
generates constitutively active forms that promoteRhoA level (data not shown).
F-actin accumulation (Watanabe et al., 1999; Tominaga(D) C2 toxin treatment blocks SRF activation by serum. SRE.FosHA
et al., submitted), and these mutants also strongly acti-cells were serum starved for 36 hr and then treated with C2 toxin
(C2I, 200 ng/ml; C2II, 400 ng/ml) for 4 hr before serum stimulation vated SRF (Figure 5C). Thus, in addition to LIMK, both
and analysis as in (C). drugs and proteins that promote F-actin accumulation
activate SRF.
SRF-VP16 and had no effect alone (Figure 5A; see also
Figure 6B). Similar results were obtained with latrunculin SRF Responds to G-Actin Levels
Although the experiments presented show that in-A (data not shown). Latrunculin B had little effect on
serum-induced ERK2 phosphorylation or stress-induced creased F-actin levels are associated with increased
SRF activity, they do not address whether SRF sensesactivation of SAPK/JNK, showing that it specifically
blocks SRF-linked signaling pathways (Figure 5B). increased F-actin level itself, an increased F-/G-actin
ratio, or a decreased G-actin level. To address this issue,Consistent with this, latrunculin treatment had no effect
on the ability of constitutively active Ras to activate a we examined the effects of two other drugs, swinholide
A and cytochalasin D. Swinholide A sequesters G-actinreporter gene system controlled by the MAPK-respon-
sive SRF cofactor TCF Elk-1 (Figure 5A, right panel). as dimers (Bubb et al., 1995; Lyubimova et al., 1997;
Saito et al., 1998), while cytochalasin D caps actin fila-Latrunculin B treatment led to a reduction in protein
accumulation, as assessed by immunoblotting, but this ments and stimulates ATP hydrolysis on G-actin (dis-
cussed by Sampath and Pollard, 1991). Both of thesewas observed with all activators (data not shown).
We next used latrunculin B and C2 toxin to test the compounds strongly activated SRF reporter genes with
prolonged activation kinetics similar to those of jasplaki-role of actin polymerization in serum- or LPA-induced
SRF activation, which are dependent on endogenous nolide (Figure 6 and data not shown). Although a recent
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overexpression was specific, since in parallel experi-
ments, serum induction of the immediate-early gene
Egr-1 was unimpaired (Figure 7A, panel 4; see below).
We used a similar approach to test whether overexpres-
sion of profilin, an actin-binding protein thought to be
involved in the polymerization process (Schluter et al.,
1997), could also affect SRF activity. Overexpression of
wild-type profilin activated expression of the reporter,
but profilin H119E, which cannot bind actin, did not
(Figure 7C; Suetsugu et al., 1998). Taken together, these
results are consistent with participation of actin itself in
the regulatory process.
A Subset of SRF Target Genes Is Regulated
by Actin Dynamics
Finally, we investigated to what extent alterations in
actin dynamics contribute to the regulation of endoge-
nous SRF target genes. Previous studies have sug-
gested that expression of two SRF target genes, cyto-
skeletal actin and vinculin (Mohun et al., 1987; Ben-Ze'evFigure 6. Activation Responds to Depletion of the G-Actin Pool
et al., 1990; Moiseyeva et al., 1993), responds to actin(A) Activation of SRF following F-actin stabilization by jasplakino-
expression levels (Reuner et al., 1995, 1996; Schevzovlide. SRE.FosHA cells maintained in 0.5% FCS were stimulated for
et al., 1995; Lyubimova et al., 1997). We therefore exam-the indicated times with either 15% FCS or 0.5 mM jasplakinolide,
with latrunculin B pretreatment where indicated. Total cell RNA pre- ined these genes, as well as the well-characterized SRF
pared at the indicated times was analyzed by RNase protection for targets c-fos and egr-1 and the srf gene itself (Spencer
3D.AFosHA and GAPDH transcripts. and Misra, 1996).
(B) SRF activation does not require increased F-actin. NIH3T3 cells
Serum induction of the endogenous c-fos gene waswere transfected with the SRF-controlled 3D.ACAT reporter, main-
essentially unimpaired by treatment with latrunculin Btained in 0.5% FCS for 24 hr, and then stimulated with 10% FCS,
or C2 toxin (Figure 8A, compare lanes 3±5 with 6±8);10 mM LPA, 0.2±0.5 mM latrunculin B (LB), 0.3±0.5 mM jasplakinolide
(Jasp), 0.03±0.1 mM swinholide A (Swin), and 0.8±2 mM cytochalasin similar results were obtained with egr-1, consistent with
D (CD) as indicated. Data shown represent the mean 6 SEM from the actin overexpression experiments (data not shown).
three independent transfections. Both the srf and vinculin genes were induced by serum,
(C) Activation of SRF by WASP and Diaphanous family proteins. although less dramatically and with slower kinetics thanNIH3T3 cells were transfected with the SRF-controlled 3D.ACAT
c-fos, reflecting the greater stability of these mRNAs. Inreporter together with expression plasmids encoding activated
contrast to c-fos induction, however, serum inductionmDia1 or mDia2 (codons 263±1255 and 255±1153, respectively),
of srf and vinculin was completely blocked by latrunculinVASP, WASP, N-WASP, or VCA (N-WASP codons 394±505) as indi-
cated and maintained in 0.5% FCS for 24 hr before harvest. Data B or C2 toxin (Figure 8A, compare lanes 3±5 with 6±8
shown represent the mean 6 SEM from three independent transfec- and 10 and 11 with 12 and 13). Induction of the c-fos
tions. gene by jasplakinolide, swinholide A, or cytochalasin D
was barely detectable (,2-fold, compared with 100-fold
induction by serum); in contrast, these drugs induced
report indicates that cytochalasin itself activates RhoA the srf and vinculin mRNAs, although somewhat less
efficiently than serum stimulation (Figure 8B; compare(Ren et al., 1999), SRF activation by cytochalasin D was
Figure 8A, lanes 1±5). Since cytoskeletal actin synthesisRhoA independent (see Figure 4C). Since swinholide A
is controlled at both the transcriptional and posttran-and cytochalasin D interact with actin but do not induce
scriptional levels (Bershadsky et al., 1995), we used aits polymerization, their ability to activate SRF strongly
reporter system to study actin regulation. The Xenopussupports a model in which SRF activation occurs in
laevis type-5 cytoskeletal actin promoter, which like theresponse to decreases in the G-actin level (see Dis-
mammalian genes contains multiple SRF-binding sitescussion).
(Mohun et al., 1987), behaved in an identical manner to
the SRF-controlled reporter genes: induction by serum
Actin Overexpression Inhibits Activation or LPA stimulation was blocked by latrunculin B, and
of SRF by Serum the gene was activated by the other actin-binding drugs,
The observation that certain drugs that bind G-actin are LIMK-1 expression, and activated RhoA (Figure 8C).
sufficient to activate SRF provides strong support for Taken together, these data demonstrate that potentia-
the idea that actin itself directly participates in SRF regu- tion of SRF activity by depletion of the cellular G-actin
lation. We reasoned that overexpression of actin might pool is necessary and sufficient for induction of some
titrate cofactors involved in SRF regulation and thereby but not all SRF target genes.
inhibit its activation. To test this idea, we increased actin
levels in SRE-FosHA cells by microinjection of a plasmid Discussion
expressing Flag-tagged actin. Upon serum stimulation,
cells overexpressing actin exhibited greatly decreased Actin Dynamics: A Convergence Point
expression of the SRF-controlled reporter gene (Figure for SRF-Linked Signal Pathways
7A, panels 1±3). Similar results were obtained using a We used an in vivo functional screen based on activation
of an SRF-controlled reporter gene to identify activatorsmicroinjected reporter (Figure 7B). The effect of actin
Control of SRF Activity via Actin Dynamics
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Figure 7. Regulation of SRF by Actin
(A) Actin overexpression inhibits SRF.
SRE.FosHA cells were microinjected with an
actin or GFP expression plasmid (100 mg/ml),
maintained in 0.5% serum for 14 hr, and then
stimulated with 10% FCS for 1 hr before stain-
ing for Flag-actin and FosHA (panels 1±3) or
Flag-actin and Egr-1 (panel 4). Data are sum-
marized at the bottom right.
(B) Cells were microinjectedwith the 3D.AFosHA
reporter (40 mg/ml) together with actin ex-
pression plasmid and treated as in (A).
(C) Profilin overexpression can activate SRF.
Cells were microinjected with the 3D.FosHA
reporter and the indicated profilin expression
plasmids (100 mg/ml) and stained for reporter
expression 14 hr later. In all panels, data are
from three independent experiments 6 SEM.
of the SRF-linked signal pathway. In addition to SRF of LIMKs and the F-actin-binding drug jasplakinolide
(Bubb et al., 1994), or are associated with de novo actinitself, we recovered a cDNA encoding the kinase domain
of the actin regulator LIMK-1 (Bernard et al., 1994; Mi- polymerization, as in the case of VASP, WASP, and Di-
aphanous family proteins (reviewed by Beckerle, 1998;zuno et al., 1994; Arber et al., 1998; Yang et al., 1998).
Expression screens of this type may facilitate identifica- Wasserman, 1998; Bi and Zigmond, 1999). The 110 resi-
due N-WASP VCA region sufficient to nucleate actintion of further regulators of both SRF and other tran-
scription factors. SRF activity can be increased by over- polymerization in vitro (Rohatgi et al., 1999) activates
SRF, and, consistent with our model, a recent studyexpression of intact LIMK-1, its close relative LIMK-2,
or either kinase domain. The only currently known func- indicates that Diaphanous family proteins are essential
components of the serum-induced RhoA-dependenttion of LIMK is to phosphorylate cofilin, which results
in the stabilization of F-actin (Carlier et al., 1997; Lappa- signaling pathway (Tominaga et al., submitted). Third,
overexpression of actin itself specifically inhibits serum-lainen and Drubin, 1997; Arber et al., 1998; Yang et al.,
1998). Both F-actin stabilization and SRF activation by induced signaling to SRF. Finally, the actin-binding
drugs swinholide A and cytochalasin D are sufficient toLIMK are inhibited by overexpression of nonphosphor-
ylatable cofilin, and this inhibition is dependent on the activate SRF, as is overexpression of the actin-binding
protein profilin. These agents do not induce polymeriza-interaction of the mutant cofilin with actin. LIMK-
induced SRF activation is also inhibited by latrunculins, tion, however, demonstrating that the sensing mecha-
nism for regulation of SRF activity must involve G-actin,drugs that prevent actin polymerization by binding actin
monomers (Coue et al., 1987). These results indicate rather than the level of F-actin or the F-/G-actin ratio.
We propose that it is depletion of the G-actin poolthat LIMK-1 potentiates SRF activity by regulating actin
dynamics. However, similar approaches demonstrated that induces SRF activation. This could occur in either
of two ways: positive regulation by a coactivator thatthat LIMK-1 is not an essential component of the signal-
ing pathway that activates SRF following serum stimula- perhaps senses G-actin level by direct physical interac-
tion, or negative regulation by a repressive complextion, so we investigated the relationship between the
LIMK- and serum-induced signal pathways. perhaps involving G-actin itself (see Figure 9). Increased
actin overexpression would inhibit SRF function by ti-Several lines of evidence demonstrate that the actin
treadmilling cycle is the point at which the LIMK- and trating such cofactors. Further experiments are required
to distinguish between these possibilities. Although cofi-serum-induced signaling pathways converge, as out-
lined in Figure 9. First, SRF activation by extracellular lin itself could in principle act as an SRF cofactor, this
would appear unlikely, because nonphosphorylatablesignals, Rho GTPases, and LIMK is blocked by inhibitors
of actin polymerization such as latrunculin and C2 toxin. cofilin mutants do not impair SRF activation by extracel-
lular signals and phosphomimetic cofilin mutants do notSecond, agents that promote F-actin accumulation acti-
vate SRF. These either stabilize F-actin, as in the case activate SRF (A. S., unpublished data). We are currently
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Figure 9. Models for SRF Regulation via the Actin Dynamics
Actin monomers are shown as wedges, cofilin as a solid circle,
and profilin as a solid rectangle. LIM kinases phosphorylate cofilin,
preventing its interaction with actin and thereby stabilizing F-actin.
Rho family GTPases regulate the activity of FH and WASP family
proteins such as mDia1/mDia2 (Rho), WASP (Cdc42), or WAVE (Rac),
which recruit profilin±actin complexes to polymerization sites. Extra-
cellular signals regulate the system via control of Rho GTPase and
possibly LIMK-1 activity. In the two models shown, SRF activity
is controlled either by an actin-interacting coactivator (ªXº) or a
repressive (actin-containing?) complex, which enables its activity
to track cellular G-actin level. For discussion, see text.
using inhibition of SRF regulation by actin overexpres-
sion as an assay with which to map regions of the mole-
cule that participate in SRF regulation. Although we think
it most likely that regulation occurs at the level of tran-
scriptional initiation, this need not necessarily be the
case, and it is interesting to note that cytoskeletal actin
has recently been found to be associated with the BAF
chromatin remodeling complex (Zhao et al., 1998).
Latrunculin and C2 toxin inhibit signal transduction to
SRF by binding to or modifying G-actin and preventing
its polymerization. In contrast, profilin, swinholide A, and
cytochalasin D, which also bind actin, are themselves
sufficient to activate SRF. We propose that this con-
trasting behavior occurs because their association with
G-actin, unlike latrunculins and C2 toxin, prevents inter-
action with the partner molecule involved in SRF regula-
tion. As yet, however, their interaction with actin remains
poorly defined. Swinholide A sequesters G-actin as di-
mers and can sever F-actin (Bubb et al., 1995; Lyubi-
mova et al., 1997; Saito et al., 1998); cytochalasin DFigure 8. Regulation of SRF Target Genes via Actin Dynamics
induces dimerization of G-actin, promotes ATP hydroly-(A) Latrunculin B and C2 toxin block serum induction of the srf and
sis, and caps filament barbed ends (see Sampath andvinculin, but not c-fos, genes. SRE.FosHA cells were maintained in
0.5% FCS for 36 hr and then treated with latrunculin B (lanes 1±8) Pollard, 1991); and binding of profilin to actin promotes
or C2 toxin (lanes 9±13) as in Figure 5. After serum stimulation for nucleotide exchange (Schluter et al., 1997). Further in-
the indicated times, c-fos (Fos), srf (SRF), vinculin, and GAPDH sights into the mechanism of SRF regulation will result
transcripts were analyzed by RNase protection. Relative transcript
from complete characterization of the interactions be-levels, as determined by PhosphorImager analysis, are shown below
tween these agents and actin.each panel.
The failure of our RhoA effector loop mutant studies to(B) Activation of SRF target genes by actin-binding drugs. Cells
maintained as in (A) were treated with 0.5 mM jasplakinolide, 0.1 mM implicate Diaphanous family proteins in SRF activation
swinholide A, or 2 mM cytochalasin D for the indicated times before (Sahai et al., 1998) may reflect either inadequacies of
RNA analysis.
(C) Control of a cytoskeletal actin promoter via actin dynamics.
NIH3T3 cells were cotransfected with a CAT reporter controlled by
the Xenopus type 5 cytoskeletal actin promoter (A431.CAT) and the 0.3 mM jasplakinolide, 0.03 mM swinholide A, or 2 mM cytochalasin
indicated activators. Following maintenance in 0.5% FCS for 16 hr, D, with latrunculin B pretreatment as indicated, and harvested. Data
cells were stimulated or not for 8 hr with 10% FCS, 10 mM LPA, shown are from a representative experiment.
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the approach or requirements for additional effectors. Our present results suggest that SRF activation via
One candidate might be phosphatidylinositol 5-kinase, actin dynamics is insufficient to activate the endoge-
which controls synthesis of PIP2, a regulator of actin nous c-fos promoter, although several previous studies
dynamics (reviewed by Van Aelst and D'Souza-Schorey, have suggested that active RhoA is necessary and suffi-
1997). cient for its activation (Hill et al., 1995; Alberts et al.,
Although our data show that serum or LPA induction 1998). Moreover, our results show that activation via
of SRF is not dependent on LIMK, the localization of actin is sufficient to induce expression of a chromo-
LIMKs at the plasma membrane suggests that they may somal SRF target, while we previously found that mi-
well be true signaling intermediates on as yet unidenti- croinjected active RhoA requires a cooperating signal
fied signaling pathways to SRF. Recent studies of LIMK to activate such a target (Alberts et al., 1998). These
have placed it downstream of both Rac and Rho disagreements may arise from use of gene transfer ap-
GTPases (Arber et al., 1998; Yang et al., 1998; S. Naru- proaches or from differences between signaling path-
miya, personal communication). However, although we ways activated using the different approaches; our re-
found that LIMK-induced SRF activation and actin ag- cent observations suggest that low levels of RhoA
gregate formation are largely Rho dependent, LIMK-1 signaling do not require cooperating signals to activate
expression alleviated cytoskeletal disruption induced by chromosomal SRF reporters (A. Alberts and R. T., un-
inactivation of Rho, indicating that LIMK activity is not published data). Further experiments are required to
dependent on Rho in our cells. We propose that LIMK- resolve these issues.
induced SRF activation is Rho dependent because the Why should some serum-induced genes be more sen-
F-actin that is sensitive to LIMK is absolutely dependent sitive to actin levels than others? Several other cytoskel-
on basal levels of RhoA activity. According to this view, etal components are inducible by serum stimulation of
RhoA-independent SRF activation by high-level LIMK 3T3 cells, including alpha-tropomyosin, fibronectin, alpha-
expression would occur because higher LIMK activity actinin, and some integrins (for example, see Ryseck et
is required to affect RhoA-independent F-actin. We are al., 1989), although the role of SRF in these events re-
currently investigating the involvement of LIMK-1 in SRF mains to be investigated. We propose that the sensitiza-
regulation in other signaling contexts, particularly those tion of cytoskeletal gene transcription to G-actin level
that, unlike the serum pathway, involve Rac. allows the expression of cytoskeletal components to
track signal-induced cytoskeletal changes. Such a mecha-
Actin Dynamics as a Regulator of SRF nism would also represent an obvious way in which muscle
Target Genes cells, where turnover of cytoskeletal components is high
Our data show that actin dynamics plays a critical role and signal-induced morphological changes frequent,
in regulation of a subset of SRF target genes. Induction could tailor synthesis of SRF-controlled cytoskeletal
of the cytoskeletal actin, vinculin, and srf genes by se- components to cell behavior.
rum is blocked by latrunculin or C2 toxin, and each
responds to actin-binding drugs in a similar way to our
SRF-controlled reporter gene. Thus, alterations in actin Experimental Procedures
dynamics appear both necessary and sufficient for regu-
Plasmidslation of these genes. These findings confirm and extend
Reporter plasmids and systems have been described previously:previous reports that G-actin levels regulate cytoskeletal
LexOP.CAT1NLexElkC, LSRE.CAT, and LMSRE.CAT (Hill et al.,actin and vinculin synthesis (Bershadsky et al., 1995;
1994); A431.CAT and 3D.ACAT (Mohun et al., 1987). 3D.ACD8 is a
Reuner et al., 1995; Schevzov et al., 1995; Lyubimova derivative of 3D.ACAT in which the CAT coding sequences are re-
et al., 1997). Vinculin overexpression correlates inversely placed by a 0.8 kb CD8 cDNA fragment encoding human CD8b
with transformation (see Rodriguez Fernandez et al., (GenBank number M36712). 3D.ACD8-neo (a gift from Art Alberts)
contains the TK.Neo gene from pREP9 (BsmI±SacII) inserted at the1992), so our results might explain the observation that
3D.ACD8 PstI site.LIMK-1 overexpression can suppress transformation
The library vector EF.NLS-VP16 is an EF.BOS derivative encoding(Higuchi et al., 1996). By contrast, and to our surprise, we
([SV40 NLS] MAPPKKKKRKVG)-S-(VP16 codons 410±490) upstreamfound that alterations in actin dynamics both contribute of a BstXI-flanked cyclin A cDNA stuffer fragment. Random primed
little to serum-induced transcription of the c-fos and cDNA from growing mouse NIH3T3 cells was synthesized by stan-
egr-1 genes and also appear insufficient for their activa- dard techniques, ligated to BstXI adaptors, and inserted into
tion. The basis for the differential sensitivity of SRF tar- EF.NLS-VP16 backbone. The library contained 4.5 3 106 indepen-
dent clones with a median cDNA insert size of z1 kb.get genes remains to be determined. It is intriguing to
The LIMK-1 kinase domain in clone Q1 deviated from the pub-note that the SRF sites in the c-fos and egr-1 promoters,
lished sequence (GenBank number MMU14166) at GG1770±unlike those of the others, contain well-defined binding
1771→CC. The 59 end of the mouse LIMK-1 cDNA was amplified
sites for the SRF cofactor TCF and that regulation of from the EF.NLS-VP16 library by PCR, sequenced, and used to
TCF activity via the ERK pathway plays a major role in reconstruct the full-length ORF; human LIMK-2 cDNA (Invitrogen)
their activation. We speculate that the association of was used following correction of a presumed PCR error at V336.
TCF with SRF may simultaneously render a promoter LIMKs were expressed with N-terminal 9E10 epitope tag using the
EF.BOS derivative EF.Tplink. EF.Fplink (N-terminal Flag epitope)sensitive to MAPK signaling pathways and relatively re-
was used to express the following ORFs (GenBank numbers in pa-fractory to signaling via actin dynamics. Indeed, in re-
rentheses): human cofilin (D00682), b-actin (NM001101), profilinporter gene experiments, inactive TCF can inhibit activa-
(NM005022), and bovine N-WASP (NM00370). Expression plasmids
tion of SRF by activated GTPases (Hill et al., 1994, 1995). for mouse mDia1 (AF094519) and mDia2 (U96963), human VASP
SRF sites in muscle-specific promoters generally lack (NM00370) and WASP (NM000377), and bovine N-WASP (NM00370)
associated TCF-binding sites, and we expect that these were gifts from Shuh Narumiya, Art Alberts, Nick Brindle, and Alan
Hall, respectively.promoters will also be sensitive to G-actin levels.
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